– UK, London – Amryt Pharma plc (AIM: AMYT, ESM: AYP), the clinical stage specialty pharma company focused on best in class treatments for orphan diseases, announces the appointment of Markus Ziener as Non-Executive Director with immediate effect. Mr Ziener is Chief Financial Officer of Software AG Stiftung.
Mr Ziener joined Software AG Stiftung in 2013 as a Director of Asset Management becoming Chief Financial Officer in August 2014. Prior to joining Software AG Stiftung, a 20.9% shareholder in Amryt, Mr Ziener worked in a number of senior roles across a broad range of industries.
Harry Stratford, Chairman of Amryt, said “I am delighted to welcome Markus to the Board of Amryt. As the Director of Asset Management within Software AG Stiftung, Markus has been a long term supporter of the Birken business and was Chairman of the Supervisory Board until the Company’s recent acquisition by Amryt. In this role, Markus was ultimately responsible for funding the development of our lead product, Episalvan, which has recently been approved in January by the European regulatory authorities for the treatment of partial thickness wounds. Together with our existing Imlan product range and the opportunity to also develop Episalvan in the rare disease Epidermolysis Bullosa, we are particularly excited about the future potential for the Amryt business.”
About Amryt Pharma plc
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or ‘orphan’ diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, propriety new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for Epidermolysis Bullosa, a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. Amryt is currently planning a phase III study of Episalvan in EB, which has been granted US and EU orphan drug designation.
Amryt’s earlier stage products are focused on developing novel, next generation somatostatin analogue peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need. These include acromegaly and Cushing’s disease.
The Company joined AIM and Dublin’s ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
